Novo Nordisk (NVO) is currently under investor scrutiny due to its recent performance and earnings potential. For the current quarter, the company is projected to report earnings of $0.79 per share, reflecting a year-over-year increase of 25.4%, with a Zacks Consensus Estimate change of +1.6% over the past 30 days. Additionally, the consensus sales estimate for the quarter stands at $9.85 billion, indicating a year-over-year growth of 24.1%.
In the last reported quarter, Novo Nordisk generated revenues of $9.52 billion, surpassing the Zacks estimate of $9.23 billion by 3.15%. This time, the company recorded earnings per share (EPS) of $0.83, beating the previous year’s $0.64. The company has a Zacks Rank of #3 (Hold), signaling that its performance may align with broader market trends in the near term.
For the current fiscal year, the consensus earnings estimate is $3.40, up 25.9% from the previous year, while the expected earnings for the next fiscal year are estimated at $4.34, indicating a growth of 27.7%.
5 Stocks Our Experts Predict Could Double In the Next Year
By submitting your email, you'll also get a free pivot & flow membership. A free daily market overview. You can unsubscribe at any time.
